Cortexyme Inc. (CRTX)
NASDAQ: CRTX
· Real-Time Price · USD
1.95
0.05 (2.63%)
At close: Aug 01, 2022, 4:00 AM
Company Description
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases.
Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection.
The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Cortexyme Inc.
| Country | United States |
| IPO Date | May 9, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 55 |
| CEO | Casey Lynch |
Contact Details
Address: 269 E Grand Ave South San Francisco, CALIFORNIA United States | |
| Website | https://www.cortexyme.com |
Stock Details
| Ticker Symbol | CRTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001662774 |
| CUSIP Number | 22053A107 |
| ISIN Number | US22053A1079 |
| Employer ID | 90-1024039 |
| SIC Code | 2836 |
Key Executives
No executives data available.Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 13, 2025 | 10-Q | Quarterly Report |
| May 13, 2025 | 8-K | Current Report |
| Apr 30, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Apr 23, 2025 | ARS | Filing |
| Apr 23, 2025 | DEFA14A | Filing |
| Apr 23, 2025 | DEF 14A | Filing |
| Apr 09, 2025 | PRE 14A | Filing |
| Mar 24, 2025 | S-8 | Filing |
| Mar 24, 2025 | 424B5 | Filing |
| Mar 24, 2025 | 10-K | Annual Report |